Market Research Logo

Artemisinin Combination - Global Market Outlook (2017-2026)

Artemisinin Combination - Global Market Outlook (2017-2026)

According tStratistics MRC, the Global Artemisinin Combination Therapy (ACT) market is accounted for $338.80 billion in 2017 and is expected treach $830.98 billion by 2026 growing at a CAGR of 10.5% during the forecast period. Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are few factors propelling for the growth of the market. However, limited number of manufacturers globally acts as a hindrance for the market growth.

Based on type, Artesunate–Mefloquine is a lucrative market for Artemisinin Combination Therapy (ACT) due tits quick spread of resistance, mediated mainly by a raise in copy number and expression of the P. falciparum multi-drug resistance (MDR) gene. This improves bioavailability and reduces vomiting. There is nformulation of mefloquine for children. Regardless of earlier restrictions there is ncause twithhold mefloquine for young children. Limited information recommends that mefloquine is perhaps secure in pregnancy.

By geography, Middle East and Africa held the largest market share in the artemisinin combination therapy owing thave large number of production base of artemisinin herbs and growing demand in malaria endemic countries which are contributing tthe expansion of the market in MEA. Though African countries, where the occurrence of malaria is high, sthey have amplified malaria control strategies, efficient treatment and control, but it still presents a huge logistical difficulty. As numerous at-risk people survive in extreme poverty in isolated areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected tboost.

Some of the key players profiled in the Artemisinin Combination Therapy (ACT) market include KPC Pharmaceuticals, Inc., Shanghai Fosun Pharmaceutical Industrial Development Company Limited, Sanofi, DesanHoldings Ltd., Calyx Chemicals and Pharmaceuticals Limited, Mylan N.V., Novartis AG, Denk Pharma GmbH & Co. KG, Hovid Berhad, Ipca Laboratories Limited, Cipla Limited and Aspen Pharmacare Holdings Limited.

Types Covered:
• Artesunate–Sulfadoxine–Pyrimethamine
• Artesunate–Mefloquine
• Artesunate–Pyronaridine
• Artemether–Lumefantrine
• Artesunate–Amodiaquine
• Dihydroartemisinin–Piperaquine

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Futuristic Market Scenario
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Artemisinin Combination Therapy (ACT) Market, By Type
5.1 Introduction
5.2 Artesunate–Sulfadoxine–Pyrimethamine
5.3 Artesunate–Mefloquine
5.4 Artesunate–Pyronaridine
5.5 Artemether–Lumefantrine
5.6 Artesunate–Amodiaquine
5.7 Dihydroartemisinin–Piperaquine
6 Global Artemisinin Combination Therapy (ACT) Market, By Geography
6.1 Introduction
6.2 North America
6.2.1 US
6.2.2 Canada
6.2.3 Mexico
6.3 Europe
6.3.1 Germany
6.3.2 UK
6.3.3 Italy
6.3.4 France
6.3.5 Spain
6.3.6 Rest of Europe
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 India
6.4.4 Australia
6.4.5 New Zealand
6.4.6 South Korea
6.4.7 Rest of Asia Pacific
6.5 South America
6.5.1 Argentina
6.5.2 Brazil
6.5.3 Chile
6.5.4 Rest of South America
6.6 Middle East & Africa
6.6.1 Saudi Arabia
6.6.2 UAE
6.6.3 Qatar
6.6.4 South Africa
6.6.5 Rest of Middle East & Africa
7 Key Developments
7.1 Agreements, Partnerships, Collaborations and Joint Ventures
7.2 Acquisitions & Mergers
7.3 New Product Launch
7.4 Expansions
7.5 Other Key Strategies
8 Company Profiling
8.1 KPC Pharmaceuticals, Inc.
8.2 Shanghai Fosun Pharmaceutical Industrial Development Company Limited
8.3 Sanofi
8.4 Desano Holdings Ltd.
8.5 Calyx Chemicals and Pharmaceuticals Limited
8.6 Mylan N.V.
8.7 Novartis AG
8.8 Denk Pharma GmbH & Co. KG
8.9 Hovid Berhad
8.10 Ipca Laboratories Limited
8.11 Cipla Limited
8.12 Aspen Pharmacare Holdings Limited
List of Tables
Table 1 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
Table 3 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
Table 4 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN)
Table 5 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN)
Table 6 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN)
Table 7 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN)
Table 8 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)
Table 9 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
Table 10 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
Table 11 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
Table 12 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN)
Table 13 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN)
Table 14 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN)
Table 15 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN)
Table 16 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)
Table 17 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
Table 18 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
Table 19 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
Table 20 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN)
Table 21 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN)
Table 22 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN)
Table 23 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN)
Table 24 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)
Table 25 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
Table 26 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
Table 27 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
Table 28 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN)
Table 29 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN)
Table 30 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN)
Table 31 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN)
Table 32 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)
Table 33 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
Table 34 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
Table 35 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
Table 36 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN)
Table 37 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN)
Table 38 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN)
Table 39 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN)
Table 40 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)
Table 41 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
Table 42 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
Table 43 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
Table 44 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN)
Table 45 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN)
Table 46 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN)
Table 47 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN)
Table 48 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report